search
Back to results

CAlcified Lesion Intervention Planning Steered by OCT. (CALIPSO)

Primary Purpose

Coronary Artery Calcification, Angioplasty

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
angioplasty
Sponsored by
Institut Mutualiste Montsouris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Calcification focused on measuring Optical Coherence Tomography, OCT, minimal stent area(MSA)

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient with chronic coronary syndrome
  2. Angiographically moderately to severely calcified target lesion, defined as follows:

    • Moderate: lesion with radio-opacities noted only during the cardiac cycle before contrast dye injection (Aksoy et al., Circ Cardiovasc Interv 2019)
    • Severe: lesion with radio-opacities seen without cardiac motion before contrast dye injection, visible on both sides of the arterial lumen(Aksoy et al., Circ Cardiovasc Interv 2019)
  3. Possibility to cross the target lesion with OCT catheter

Exclusion Criteria:

  1. On-going cardiogenic shock
  2. Acute coronary syndrome related to target lesion
  3. Severe renal failure (Creatinine clearance: 30 ml/min/m2)
  4. Impossibility to cross target lesion with OCT catheter & balloons,
  5. Indication for Rotablator device as first line therapy
  6. Pregnancy
  7. Age < 18 y
  8. Denial to provide consent

Sites / Locations

  • Institut Mutualiste montsourisRecruiting
  • Ch de BastiaRecruiting
  • CHU de BesançonRecruiting
  • CHU de BordeauxRecruiting
  • Clinique Saint AugustinRecruiting
  • CHU de Clermont-FerrandRecruiting
  • Hôpital Louis PasteurRecruiting
  • L'Hôpital Privé du ConfluentRecruiting
  • CHU NîmesRecruiting
  • Polyclinique les FleursRecruiting
  • CHU de PoitiersRecruiting
  • Clinique Saint-HilaireRecruiting
  • Institut Arnaud Tzanck,Recruiting
  • Clinique PasteurRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

angiography-guided group

OCT-guided group

Arm Description

the treatment (including lesion preparation, stent sizing and post implantation optimization) will be performed by angiography. Once the result is considered optimal by the operator, a control OCT run will be acquired.

a preliminary OCT run will be recorded. An initial predilation with 1.5 to 2.0 mm balloon could be accepted in order to facilitate OCT catheter delivery through the target lesion. The PCI strategy will be guided by a pre-defined algorithm based on initial OCT findings. Post PCI result will be assessed by control OCT and potential optimization steps could be applied according to the results. The MLD-MAX optimization approach will be applied. Final OCT run will be performed at the end of the procedure.

Outcomes

Primary Outcome Measures

The primary endpoint of the CALIPSO study is the minimal stent area (MSA) on the final OCT run
The crude minimal stent area (MSA) will be measured along the stent on the target lesion. Stent geometric expansion will be evaluated by the DOCTORS criteria for non-bifurcated segments (Meneveau et, Circulation 2016) and LEMON criteria for bifurcated segments (Amabile et al;, Eurointervention 2020).

Secondary Outcome Measures

Geometrical stent expansion (%) according to the DOCTORS or LEMON criteria
After the stent is deployed, the blood flow dynamics influence the mechanics by compressing and expanding the structure.
Residual post PCI (Percutaneous Coronary Intervention)stenosis (assessed by QCA methods)
Qualitative Comparative Analysis (QCA) is a methodology that enables the analysis of multiple cases in complex situations
Residual major struts malapposition: crude incidence and quantification
malapposition was defined as a lack of contact of at least 1 strut with the underlying vessel wall (at least 150 μm, in the absence of a side branch) with evidence of blood flow behind the strut. It was classified as "major" malapposition if there was evidence of at least 30% of the struts in one frame.
Major adverse cardiovascular events at 30 days and 1 year
Cardiovascular death + Any myocardial infarction + need for re-intervention on the target lesion (TLR)
Peri-procedural MI according to the SCAI definition (23)
according to the SCAI definition (Moussa et al., Journal of the American College of Cardiology 2013)
Coronary artery perforation: incidence
Coronary perforation was defined as evidence of extravasation of dye or blood from the coronary artery during or following the interventional procedure
Radiation dose
Differences in dose radiation used during le procedure
Total Contrast medium volume
Differences in amount of contrast drug used during le procedure
Procedure duration
differences in duration (time) of the procedure

Full Information

First Posted
March 8, 2022
Last Updated
November 14, 2022
Sponsor
Institut Mutualiste Montsouris
Collaborators
Abbott
search

1. Study Identification

Unique Protocol Identification Number
NCT05301218
Brief Title
CAlcified Lesion Intervention Planning Steered by OCT.
Acronym
CALIPSO
Official Title
CAlcified Lesion Intervention Planning Steered by OCT.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2021 (Actual)
Primary Completion Date
December 15, 2023 (Anticipated)
Study Completion Date
December 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Mutualiste Montsouris
Collaborators
Abbott

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Calcified lesions are very frequent among coronary artery disease stenotic lesions. The prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. Calcified lesions are very frequent among coronary artery disease stenotic lesions. The prevalence of calcifications ranges from 30 to 40% (by angiography evaluation) but is higher when analyzed by intra coronary imaging. The presence of calcifications increases the risk of adverse evolution after PCI , including stent restenosis, thrombosis and need for repeat revascularisation. Specific and appropriate tools can be used for calcified lesions management , including high pressure non compliant balloons, intravascular lithotripsy and rotablator. Intra vascular OCT has a high sensitivity and specificity for calcium detection among coronary artery lesions. Compared to IVUS, OCT allows a better quantification of calcium sheets (depth extension ) . Several intra coronary imaging based calcified lesions management algorithms have been proposed , but none have been validated in clinical practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Calcification, Angioplasty
Keywords
Optical Coherence Tomography, OCT, minimal stent area(MSA)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
angiography-guided group
Arm Type
Active Comparator
Arm Description
the treatment (including lesion preparation, stent sizing and post implantation optimization) will be performed by angiography. Once the result is considered optimal by the operator, a control OCT run will be acquired.
Arm Title
OCT-guided group
Arm Type
Experimental
Arm Description
a preliminary OCT run will be recorded. An initial predilation with 1.5 to 2.0 mm balloon could be accepted in order to facilitate OCT catheter delivery through the target lesion. The PCI strategy will be guided by a pre-defined algorithm based on initial OCT findings. Post PCI result will be assessed by control OCT and potential optimization steps could be applied according to the results. The MLD-MAX optimization approach will be applied. Final OCT run will be performed at the end of the procedure.
Intervention Type
Procedure
Intervention Name(s)
angioplasty
Intervention Description
Coronary angioplasty, also called percutaneous coronary intervention, is a procedure used to open clogged heart arteries. Angioplasty uses a tiny balloon catheter that is inserted in a blocked blood vessel to help widen it and improve blood flow to the heart
Primary Outcome Measure Information:
Title
The primary endpoint of the CALIPSO study is the minimal stent area (MSA) on the final OCT run
Description
The crude minimal stent area (MSA) will be measured along the stent on the target lesion. Stent geometric expansion will be evaluated by the DOCTORS criteria for non-bifurcated segments (Meneveau et, Circulation 2016) and LEMON criteria for bifurcated segments (Amabile et al;, Eurointervention 2020).
Time Frame
During the procedure
Secondary Outcome Measure Information:
Title
Geometrical stent expansion (%) according to the DOCTORS or LEMON criteria
Description
After the stent is deployed, the blood flow dynamics influence the mechanics by compressing and expanding the structure.
Time Frame
during procedure
Title
Residual post PCI (Percutaneous Coronary Intervention)stenosis (assessed by QCA methods)
Description
Qualitative Comparative Analysis (QCA) is a methodology that enables the analysis of multiple cases in complex situations
Time Frame
during procedure
Title
Residual major struts malapposition: crude incidence and quantification
Description
malapposition was defined as a lack of contact of at least 1 strut with the underlying vessel wall (at least 150 μm, in the absence of a side branch) with evidence of blood flow behind the strut. It was classified as "major" malapposition if there was evidence of at least 30% of the struts in one frame.
Time Frame
during procedure
Title
Major adverse cardiovascular events at 30 days and 1 year
Description
Cardiovascular death + Any myocardial infarction + need for re-intervention on the target lesion (TLR)
Time Frame
at 30 days and 1 year
Title
Peri-procedural MI according to the SCAI definition (23)
Description
according to the SCAI definition (Moussa et al., Journal of the American College of Cardiology 2013)
Time Frame
during procedure
Title
Coronary artery perforation: incidence
Description
Coronary perforation was defined as evidence of extravasation of dye or blood from the coronary artery during or following the interventional procedure
Time Frame
during the procedure and During the full participation period (1 year).]
Title
Radiation dose
Description
Differences in dose radiation used during le procedure
Time Frame
during procedure
Title
Total Contrast medium volume
Description
Differences in amount of contrast drug used during le procedure
Time Frame
during procedure
Title
Procedure duration
Description
differences in duration (time) of the procedure
Time Frame
24th post-operative hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with chronic coronary syndrome Angiographically moderately to severely calcified target lesion, defined as follows: Moderate: lesion with radio-opacities noted only during the cardiac cycle before contrast dye injection (Aksoy et al., Circ Cardiovasc Interv 2019) Severe: lesion with radio-opacities seen without cardiac motion before contrast dye injection, visible on both sides of the arterial lumen(Aksoy et al., Circ Cardiovasc Interv 2019) Possibility to cross the target lesion with OCT catheter Exclusion Criteria: On-going cardiogenic shock Acute coronary syndrome related to target lesion Severe renal failure (Creatinine clearance: 30 ml/min/m2) Impossibility to cross target lesion with OCT catheter & balloons, Indication for Rotablator device as first line therapy Pregnancy Age < 18 y Denial to provide consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolas Amabile, MD PhD
Phone
0156616983
Ext
33
Email
nicolas.amabile@imm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Silvia Burbassi, PhD
Phone
0156616983
Ext
33
Email
silvia.burbassi@imm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolas Amabile, MD PhD
Organizational Affiliation
Institut Mutualiste Montsouris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut Mutualiste montsouris
City
Paris
State/Province
Ile De France
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvia Burbassi, PhD
Phone
0156616983
Ext
33
Email
silvia.burbassi@imm.fr
First Name & Middle Initial & Last Name & Degree
Nicolas Amabile, MD PhD
Facility Name
Ch de Bastia
City
Bastia
ZIP/Postal Code
20600
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ziad Boueri, MD
Facility Name
CHU de Besançon
City
Besançon
ZIP/Postal Code
25000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Meneveau, MD
Facility Name
CHU de Bordeaux
City
Bordeaux
ZIP/Postal Code
33000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Séguy, MD
Facility Name
Clinique Saint Augustin
City
Bordeaux
ZIP/Postal Code
33200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frederic Casassus, MD
Facility Name
CHU de Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Géraud SOUTEYRAND, MD
Facility Name
Hôpital Louis Pasteur
City
Le Coudray
ZIP/Postal Code
28630
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grégoire RANGé Rangé, MD
Facility Name
L'Hôpital Privé du Confluent
City
Nantes
ZIP/Postal Code
44000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erwan BRESSOLLETTE, MD
Facility Name
CHU Nîmes
City
Nîmes
ZIP/Postal Code
30029
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume Cayla, MD
Facility Name
Polyclinique les Fleurs
City
Ollioules
ZIP/Postal Code
83190
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Commeau, MD
Facility Name
CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sébastien Levesque, MD
Facility Name
Clinique Saint-Hilaire
City
Rouen
ZIP/Postal Code
76000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Quentin LANDOLFF, MD
Facility Name
Institut Arnaud Tzanck,
City
Saint-Laurent-du-Var
ZIP/Postal Code
06700
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julien ADJEDJ, MD
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31300
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin HONTON, MD

12. IPD Sharing Statement

Learn more about this trial

CAlcified Lesion Intervention Planning Steered by OCT.

We'll reach out to this number within 24 hrs